The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    PSIL201
Previous Study | Return to List | Next Study

PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04353921
Recruitment Status : Terminated (Low enrollment and inability to achieve statistical significance)
First Posted : April 21, 2020
Last Update Posted : December 2, 2022
Sponsor:
Information provided by (Responsible Party):
Usona Institute

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a Phase 2 double-blind, long-term observational follow-up study of participants from Study PSIL201. Participants providing informed consent will be enrolled into this study and will complete web surveys and telephone interviews conducted by one central site at the following time intervals: months 2, 3, 4, 5 and 6 (± 7 days for each assessment) and months 8, 10, 12, 14, 16, 18, 20, 22 and 24 (± 14 days for each assessment).

Condition or disease Intervention/treatment
Major Depressive Disorder Other: No intervention will be administered as part of this study.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 24 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: A Two-Year Observational Follow-up Study of Subjects With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control
Actual Study Start Date : June 30, 2020
Actual Primary Completion Date : October 18, 2022
Actual Study Completion Date : October 18, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Niacin

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Single-Dose of Psilocybin Other: No intervention will be administered as part of this study.
No intervention will be administered as part of this study.
Niacin-Control Other: No intervention will be administered as part of this study.
No intervention will be administered as part of this study.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Montgomery-Asberg Depression Rating Scale [ Time Frame: 6 Months post-dosing in PSIL201 ]
    Between-group difference in mean change from baseline (prior to dosing in PSIL201) in Montgomery-Asberg Depression Rating Scale (MADRS)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Enrollment is constrained to those participants dosed with investigational drug (psilocybin or niacin) in Study PSIL201.
Criteria

Inclusion Criteria:

  • Enrollment and intervention with the investigational drug in Study PSIL201

Exclusion Criteria:

  • Inability or unwillingness to complete study procedures, including regular completion of web surveys and telephone interviews with study personnel
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04353921


Locations
Layout table for location information
United States, Florida
Segal Trials
Lauderhill, Florida, United States, 33319
Sponsors and Collaborators
Usona Institute
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Usona Institute
ClinicalTrials.gov Identifier: NCT04353921    
Other Study ID Numbers: PSIL201-LTFU
First Posted: April 21, 2020    Key Record Dates
Last Update Posted: December 2, 2022
Last Verified: November 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depression
Depressive Disorder, Major
 Mood Disorders
Mental Disorders
Behavioral Symptoms